Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management

Ann Rheum Dis. 2020 Jun;79(6):724-726. doi: 10.1136/annrheumdis-2020-217407. Epub 2020 Apr 29.

Abstract

Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients.

Keywords: autoimmune diseases; hydroxychloroquine; scleroderma; systemic.

Publication types

  • Practice Guideline

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / physiopathology*
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects
  • Lung Diseases, Interstitial / immunology
  • Lung Diseases, Interstitial / virology
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / physiopathology*
  • Pneumonia, Viral / virology
  • Respiratory Distress Syndrome / drug therapy
  • Respiratory Distress Syndrome / virology
  • SARS-CoV-2
  • Scleroderma, Systemic / epidemiology
  • Scleroderma, Systemic / immunology
  • Scleroderma, Systemic / therapy*
  • Scleroderma, Systemic / virology*

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • tocilizumab